Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.72 |
| ▸ | PGR | P06401 | 6/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | IL6 | P05231 | 1/20 | 0.51 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | GLUL | P15104 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602408 | 1.00 | CYP3A4 (0.72) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL2482647 | 0.91 | CYP3A4 (0.69) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL9602646 | 0.91 | PGR (0.59) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL21145516 | 0.90 | CYP3A4 (0.78) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL10798820 | 0.88 | CYP3A4 (0.74) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL10798815 | 0.88 | CYP3A4 (0.74) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL9789817 | 0.88 | NR3C1 (0.69) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL3406698 | 0.86 | CYP3A4 (0.81) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL3406702 | 0.86 | CYP3A4 (0.81) | CYP3A4HIF1ANR3C1PGRHSD17B10 | |
| SCHEMBL10944298 | 0.86 | HIF1A (0.70) | CYP3A4HIF1ANR3C1PGRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4119561-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20210369701-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| EP-3851107-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210169872-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10973813-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3590517-B1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10456392-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20140038926-A1 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | CORCEPT THERAPEUTICS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2013177559-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2661175-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | Corcept Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| CN-103298343-A | Combination steroid and glucocorticoid receptor antagonist therapy | CORCEPT THERAPEUTICS INC | 2013-09-11 | — | — | CN | disclosed |
| US-20130012486-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | Corcept Therapeutics, Inc. (019904) (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012094618-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | CORCEPT THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-20040006240-A1 | Process to prepare 11beta,17alpha ,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | PHARMACIA & UPJOHN COMPANY | 2004-01-08 | — | — | US | disclosed |
| EP-0301966-B1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEGENERATIVE JOINT DISEASE | Trager, Seymour F. (US) | 1992-12-02 | — | — | EP | disclosed |
| US-4828828-A | ANTIARTHRITIC | TRAGER SEYMOUR F (US) | 1989-05-09 | — | — | US | disclosed |
| EP-0301966-A2 | Pharmaceutical compositions for treating degenerative joint disease | Trager, Seymour F. (US) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169872-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, NR5A1 | CYP3A4 374/4885HIF1A 4646/4885NR3C1 1/4885 |
| US-11648245-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | CYP3A4 1984/4885HIF1A 4622/4885NR3C1 1/4885 |
| US-20210369701-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | CYP3A4 1984/4885HIF1A 4622/4885NR3C1 1/4885 |
| US-10973813-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | CYP3A4 374/4885HIF1A 4646/4885NR3C1 1/4885 |
| US-11576907-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | CYP3A4 374/4885HIF1A 4646/4885NR3C1 1/4885 |
| US-20140038926-A1 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | NR3C1, NR3C2, NR5A1 | CYP3A4 374/4885HIF1A 4646/4885NR3C1 1/4885 |
| US-10456392-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, NR3C2, NR5A1 | CYP3A4 374/4885HIF1A 4646/4885NR3C1 1/4885 |
| US-20130012486-A1 | COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY | NR3C1, NR3C2, NR5A1 | CYP3A4 3413/4885HIF1A 1062/4885NR3C1 1/4885 |
| US-20040006240-A1 | Process to prepare 11beta,17alpha ,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione 21-acetate | CYP17A1, CYP51A1, HSD17B11 | CYP3A4 96/4885HIF1A 548/4885NR3C1 117/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | CYP3A4 1984/4885HIF1A 4622/4885NR3C1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.